177 related articles for article (PubMed ID: 37051474)
1. A Rare Case of Incidentally Diagnosed Pulmonary Inflammatory Myofibroblastic Tumour with Dramatic Response to Crizotinib in a Postpartum Woman.
Yorke J; Solanki K; Theegala V; Georges T; Sinha AK; Asberry DE; El Abbassi A
Eur J Case Rep Intern Med; 2023; 10(4):003626. PubMed ID: 37051474
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report.
Nagumo Y; Maejima A; Toyoshima Y; Komiyama M; Yonemori K; Yoshida A; Fujimoto H
Int J Surg Case Rep; 2018; 48():1-4. PubMed ID: 29758320
[TBL] [Abstract][Full Text] [Related]
3. Individualized targeted treatment in a case of a rare TFG::ROS1 fusion positive inflammatory myofibroblastic tumor (IMT).
Sommer S; Schmutz M; Schaller T; Mayr P; Dintner S; Märkl B; Huss R; Golas MM; Kuhlen M; Jordan F; Claus R; Heinrich B
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1916. PubMed ID: 37950626
[TBL] [Abstract][Full Text] [Related]
4. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
5. Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.
Comandini D; Catalano F; Grassi M; Pesola G; Bertulli R; Guadagno A; Spina B; Mascherini M; De Cian F; Pistoia F; Rebuzzi SE
Front Oncol; 2021; 11():658327. PubMed ID: 34211840
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring
Zhao T; Zhang X; Liu X; Ren M; Cheng Y; Wang J; Luo Z
Front Oncol; 2023; 13():1147974. PubMed ID: 37035208
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.
Ogata M; Hatachi Y; Ogata T; Satake H; Imai Y; Yasui H
Intern Med; 2019 Apr; 58(7):1029-1032. PubMed ID: 30449794
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Myofibroblastic Tumor: A Rare Presentation and an Effective Treatment with Crizotinib.
Khalil S; Ghafoor T; Raja AKF
Case Rep Oncol Med; 2020; 2020():6923103. PubMed ID: 32695536
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib in ALK
Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
[TBL] [Abstract][Full Text] [Related]
10. ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations.
Debonis SA; Bongiovanni A; Pieri F; Fausti V; De Vita A; Riva N; Gurrieri L; Vanni S; Diano D; Mercatali L; Ibrahim T
Medicine (Baltimore); 2021 May; 100(20):e25972. PubMed ID: 34011083
[TBL] [Abstract][Full Text] [Related]
11. Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT).
Ingley KM; Hughes D; Hubank M; Lindsay D; Plumb A; Cox R; Chesler L; Strauss SJ
Lung Cancer; 2021 Aug; 158():151-155. PubMed ID: 34059352
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report.
López de Sa A; Pascual A; Garcia Santos J; Mendez R; Bellon M; Ramirez M; Matute F; Del Arco C; Manzano A; Coronado P; Casado A; Marquina G
World J Surg Oncol; 2021 Nov; 19(1):331. PubMed ID: 34801049
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
[TBL] [Abstract][Full Text] [Related]
14. Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor.
Mai S; Xiong G; Diao D; Wang W; Zhou Y; Cai R
Lung Cancer; 2019 Feb; 128():101-104. PubMed ID: 30642440
[TBL] [Abstract][Full Text] [Related]
15. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges.
Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R
Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015
[TBL] [Abstract][Full Text] [Related]
17. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.
Hornick JL; Sholl LM; Dal Cin P; Childress MA; Lovly CM
Mod Pathol; 2015 May; 28(5):732-9. PubMed ID: 25612511
[TBL] [Abstract][Full Text] [Related]
18. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
[TBL] [Abstract][Full Text] [Related]
19. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
20. Sustained complete response on crizotinib in primary lung inflammatory myofibroblastic tumor - Case report and literature review.
Mittal A; Gupta A; Dhamija E; Barwad A; Rastogi S
Monaldi Arch Chest Dis; 2021 Mar; 91(3):. PubMed ID: 33794589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
